SG190438A1 - Histone inhibition - Google Patents

Histone inhibition Download PDF

Info

Publication number
SG190438A1
SG190438A1 SG2013041579A SG2013041579A SG190438A1 SG 190438 A1 SG190438 A1 SG 190438A1 SG 2013041579 A SG2013041579 A SG 2013041579A SG 2013041579 A SG2013041579 A SG 2013041579A SG 190438 A1 SG190438 A1 SG 190438A1
Authority
SG
Singapore
Prior art keywords
sulfate
histone
group
polyanion
monosaccharide
Prior art date
Application number
SG2013041579A
Other languages
English (en)
Inventor
Ross Wentworth Stephens
Christopher Richard Parish
Craig Geoffrey Freeman
Timothy John Senden
Original Assignee
Univ Australian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Australian filed Critical Univ Australian
Publication of SG190438A1 publication Critical patent/SG190438A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
SG2013041579A 2010-12-01 2011-11-29 Histone inhibition SG190438A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41882610P 2010-12-01 2010-12-01
PCT/AU2011/001550 WO2012071611A1 (en) 2010-12-01 2011-11-29 Histone inhibition

Publications (1)

Publication Number Publication Date
SG190438A1 true SG190438A1 (en) 2013-07-31

Family

ID=46171086

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2013041579A SG190438A1 (en) 2010-12-01 2011-11-29 Histone inhibition

Country Status (15)

Country Link
US (1) US9226939B2 (enExample)
EP (1) EP2646037B1 (enExample)
JP (2) JP2014501730A (enExample)
KR (1) KR101956335B1 (enExample)
CN (1) CN103402526B (enExample)
AU (1) AU2011335881B2 (enExample)
BR (1) BR112013013544B1 (enExample)
CA (1) CA2819642C (enExample)
DK (1) DK2646037T3 (enExample)
ES (1) ES2710857T3 (enExample)
HU (1) HUE043546T2 (enExample)
IL (1) IL226667A (enExample)
NZ (1) NZ611316A (enExample)
SG (1) SG190438A1 (enExample)
WO (1) WO2012071611A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3105593B2 (ja) 1991-10-18 2000-11-06 東海パルプ株式会社 パルパー制御装置
WO2018165656A1 (en) 2017-03-10 2018-09-13 The University Of North Carolina At Chapel Hill Short-acting heparin-based anticoagulant compounds and methods
US11993627B2 (en) 2017-07-03 2024-05-28 The University Of North Carolina At Chapel Hill Enzymatic synthesis of homogeneous chondroitin sulfate oligosaccharides
US11865137B2 (en) 2017-11-03 2024-01-09 The University Of North Carolina At Chapel Hill Sulfated oligosaccharides having anti-inflammatory activity
US11628179B2 (en) * 2017-12-15 2023-04-18 The Australian National University Compounds for treating and preventing extracellular histone mediated pathologies
WO2019246264A1 (en) * 2018-06-20 2019-12-26 The University Of North Carolina At Chapel Hill Cell protective methods and compositions
WO2020033824A1 (en) * 2018-08-09 2020-02-13 University Of Vermont And State Agricultural College Inhibitors of acute severe inflammatory conditions
CA3130405A1 (en) * 2019-02-25 2020-09-03 The Australian National University Compounds for treating and preventing net associated complications
WO2021097345A1 (en) 2019-11-13 2021-05-20 The University Of North Carolina At Chapel Hill Heparan sulfate (hs) oligosaccharides effect in liver ischemia reperfusion injury
WO2022116981A1 (zh) * 2020-12-01 2022-06-09 远大医药(中国)有限公司 一种聚阴离子纤维二糖苷类化合物的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4847338A (en) * 1985-03-28 1989-07-11 University Of Iowa Research Foundation Low molecular weight heparin fragments as inhibitors of complement activation
DK505488D0 (da) * 1987-12-21 1988-09-09 Bar Shalom Daniel Middel og anvendelse af samme
US5583121A (en) 1994-01-12 1996-12-10 Michigan State University Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes
DE69514059T2 (de) 1994-09-21 2000-05-25 Allrad No. 19 Pty Ltd., Canberra Eine elektrostatische Niederschlagsvorrichtung
AUPN261895A0 (en) 1995-04-28 1995-05-18 Australian National University, The Preparation and use of sulfated oligosaccharides
WO1999004826A1 (en) 1997-07-24 1999-02-04 The Australian National University Method for detection of fibrin clots
ITMI20021294A1 (it) * 2002-06-12 2003-12-12 Inalco Spa Polisaccaridi batterici o-solfatati e loro uso
US20050282775A1 (en) 2004-06-16 2005-12-22 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome
US7468358B2 (en) * 2004-06-16 2008-12-23 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (HIT) syndrome
WO2006015171A2 (en) * 2004-07-28 2006-02-09 The Texas A & M University System Use of glycosoaminoglycans for the prevention and treatment of sepsis
PT1877105E (pt) 2005-04-29 2013-11-11 Univ Australian Método para formar uma composição radioativa injetável de partículas radioativas encapsuladas em carbono
EP1747785A1 (en) * 2005-07-28 2007-01-31 Istituto Clinico Humanitas Cyclodextrins for blood detoxification
WO2007062403A2 (en) 2005-11-28 2007-05-31 Vernon D Rowe Compositions useful for reducing nephrotoxicity and methods of use thereof
WO2007095688A1 (en) 2006-02-23 2007-08-30 The Australian National University Methods for increasing the number of circulating cells
GB2450087A (en) * 2007-06-11 2008-12-17 Diosamine Dev Corp Use of sulphated saccharides in the treatment of inflammatory and/or auto-immune diseases
EP2209485B1 (en) 2007-11-06 2016-03-30 Oklahoma Medical Research Foundation Extracellular histones as biomarkers for prognosis and molecular targets for therapy
JP5645085B2 (ja) 2008-04-24 2014-12-24 ジ オーストラリアン ナショナル ユニバーシティー マクロ分子を放射性標識化するための方法
JP2011256111A (ja) * 2008-10-03 2011-12-22 Hayashibara Biochem Lab Inc 敗血症の予防及び治療剤

Also Published As

Publication number Publication date
BR112013013544B1 (pt) 2020-09-29
KR20130121877A (ko) 2013-11-06
WO2012071611A1 (en) 2012-06-07
JP2014501730A (ja) 2014-01-23
US9226939B2 (en) 2016-01-05
EP2646037B1 (en) 2019-01-09
IL226667A (en) 2017-02-28
KR101956335B1 (ko) 2019-03-08
ES2710857T3 (es) 2019-04-29
JP2016193917A (ja) 2016-11-17
NZ611316A (en) 2014-12-24
BR112013013544A2 (pt) 2016-10-11
DK2646037T3 (en) 2019-03-04
JP6142039B2 (ja) 2017-06-07
AU2011335881A1 (en) 2013-06-20
HUE043546T2 (hu) 2019-08-28
CN103402526A (zh) 2013-11-20
CA2819642A1 (en) 2012-06-07
CA2819642C (en) 2019-07-16
AU2011335881B2 (en) 2016-07-14
CN103402526B (zh) 2016-01-20
US20130338097A1 (en) 2013-12-19
EP2646037A1 (en) 2013-10-09
EP2646037A4 (en) 2015-03-18

Similar Documents

Publication Publication Date Title
AU2011335881B2 (en) Histone inhibition
Krishnamurthy et al. Glycopeptide analogues of PSGL-1 inhibit P-selectin in vitro and in vivo
Laurent et al. The properties and turnover of hyaluronan
US6391857B1 (en) Methods and compositions for endothelial binding
JP2022058417A (ja) 治療において使用するためのスルファミドリンカーを含むバイオコンジュゲート
US7507723B2 (en) Hyaluronic acid oligosaccharide fractions and drugs containing the same
EP0270317A2 (en) Pharmaceutical compositions for the treatment of diseases caused by viruses
CZ341097A3 (cs) Sulfatované oligosacharidy, způsob jejich výroby a použití
CN105504097B (zh) 一种硫酸化肝素寡糖及其制备方法和应用
JPH06506685A (ja) 新規な非抗凝固剤ヘパリン誘導体
JPH01503548A (ja) ヘパリン誘導体
JP2023166387A (ja) 短時間作用型ヘパリンベースの抗凝集剤化合物及び方法
US20050282775A1 (en) Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome
JP2021517582A (ja) 細胞外ヒストンによって媒介される病理を処置及び予防するための化合物
JP5508421B2 (ja) 薬剤として有用なポリ硫酸カルボキシエチル化シクロデキストリン
Alban et al. PS3, A semisynthetic Β-1, 3-glucan sulfate, diminishes contact hypersensitivity responses through inhibition of L-and P-selectin functions
JP2014141517A (ja) ポリシアル酸脱n−アセチラーゼの阻害剤及びその使用方法
WO2005092348A1 (ja) ヘパリン様オリゴ糖含有hgf産生促進薬剤
US20060211651A1 (en) Persulfated oligosaccharide acting on selectins and chemokine
JPH07502011A (ja) 免疫抑制性および寛容原性のオリゴ糖誘導体
HK1188125B (en) Use of polyanions to inhibit the cytotoxic activity of histones in the treatment of sepsis
HK1188125A (en) Use of polyanions to inhibit the cytotoxic activity of histones in the treatment of sepsis
JP2003535965A (ja) インフルエンザウイルス結合性シアル化オリゴ糖含有物質およびその用途
PT1917018E (pt) Sulfato de inulina para o tratamento de osteoartrite
JPH09255576A (ja) 抗炎症剤